289483-79-0

Basic information

• Product Name: 4-methyl-7-nitro-1H-indole-2-carboxylic acid
• Synonyms: 4-methyl-7-nitro-1H-indole-2-carboxylic acid
• CAS NO: 289483-79-0
• Molecular Formula: C10H8N2O4
• Molecular Weight: 220.18152
• Mol File: 289483-79-0.mol

Chemical Properties

• Boiling Point: 532.3±45.0 °C(Predicted)
• Appearance: /
• Density: 1.544±0.06 g/cm3(Predicted)
• Storage Temp.: 2-8°C
• PKA: 4.12±0.30(Predicted)
• CAS DataBase Reference: 4-methyl-7-nitro-1H-indole-2-carboxylic acid(CAS DataBase Reference)
• NIST Chemistry Reference: 4-methyl-7-nitro-1H-indole-2-carboxylic acid(289483-79-0)
• EPA Substance Registry System: 4-methyl-7-nitro-1H-indole-2-carboxylic acid(289483-79-0)

Safety Data

• Hazardous Substances Data: 289483-79-0(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical and Agrochemical Synthesis:
4-methyl-7-nitro-1H-indole-2-carboxylic acid is used as a key intermediate in the synthesis of pharmaceuticals and agrochemicals due to its unique structural features and reactivity, contributing to the development of new drugs and pesticides.
Used as a Fluorescent Marker in Research:
In biological and medical research, 4-methyl-7-nitro-1H-indole-2-carboxylic acid serves as a fluorescent marker, enabling the tracking and visualization of cellular processes and molecular interactions, thus aiding in the advancement of scientific understanding.
Used in Anti-inflammatory and Anti-cancer Applications:
4-methyl-7-nitro-1H-indole-2-carboxylic acid has been studied for its potential as an anti-inflammatory and anti-cancer agent, with its unique chemical properties possibly offering therapeutic benefits in the treatment of inflammation and cancer.
Safety Precautions:
It is crucial to handle 4-methyl-7-nitro-1H-indole-2-carboxylic acid with care, as it may pose health risks if ingested, inhaled, or comes into contact with the skin, necessitating proper safety measures during its use and disposal.

Upstream product

• 61149-52-8 4-methyl-7-nitro-indole-2-carboxylic acid ethyl ester 

Relevant articles and documents

Integrin expression inhibitors

The present invention provides an integrin expression inhibitor, and an agent for treating arterial sclerosis, psoriasis, cancer, retinal angiogenesis, diabetic retinopathy or inflammatory diseases, an anticoagulant, or a cancer metastasis suppressor on the basis of an integrin inhibitory action. Namely, it provides an integrin expression inhibitor comprising, as an active ingredient, a sulfonamide compound represented by the following formula (I), a pharmacologically acceptable salt thereof or a hydrate of them. In the formula, B means a C6-C10 aryl ring or 6- to 10-membered heteroaryl ring which may have a substituent and in which a part of the ring may be saturated; K means a single bond, —CH═CH— or —(CR4bR5b)mb— (wherein R4b and R5b are the same as or different from each other and each means hydrogen atom or a C1-C4 alkyl group; and mb means an integer of 1 or 2); R1 means hydrogen atom or a C1-C6 alkyl group; Z means a single bond or —CO—NH—; and R means a C6-C10 aryl ring or 6- to 10-membered heteroaryl ring which may have a substituent and in which a part of the ring may be saturated, respectively.

Sulfonamide-containing indole compounds

The present invention creates a novel antiangiogenic agent and provides an antitumor agent which shows high safety as compared with conventional antitumor agents, has a sure effect and is able to be administered for a long period. That is, it provides an indole compound represented by the following formula (I), its pharmacologically acceptable salt or hydrates thereof. In the formula, R1 represents hydrogen atom, a halogen atom or cyano group; R2 and R3 are the same as or different from and each represents hydrogen atom, a C1-C4 lower alkyl group or a halogen atom; R4 represents hydrogen atom or a C1-C4 lower alkyl group; and the ring A represents cyanophenyl group, aminosulfonylphenyl group, aminopyridyl group, aminopyrimidyl group, a halopyridyl group or cyanothiophenyl group, provided that the case where all of R1, R2 and R3 are hydrogen atoms, where both R2 and R3 are hydrogen atoms or where the ring A is aminosulfonyl group and both R1 and R2 are halogen atoms is excluded. Further, when the ring A is cyanophenyl group, 2-amino-5-pyridyl group or a 2-halo-5-pyridyl group and R1 is cyano group or a halogen atom, at least one of R2 and R3 should not be a hydrogen atom.

INTEGRIN EXPRESSION INHIBITORS

The present invention provides an integrin expression inhibitor, and an agent for treating arterial sclerosis, psoriasis, cancer, retinal angiogenesis, diabetic retinopathy or inflammatory diseases, an anticoagulant, or a cancer metastasis suppressor on the basis of an integrin inhibitory action. Namely, it provides an integrin expression inhibitor comprising, as an active ingredient, a sulfonamide compound represented by the following formula (I), a pharmacologically acceptable salt thereof or a hydrate of them. In the formula, B means a C6-C10 aryl ring or 6- to 10-membered heteroaryl ring which may have a substituent and in which a part of the ring may be saturated; K means a single bond, -CH=CH- or - (CR4bR5b)mb- (wherein R4b and R5b are the same as or different from each other and each means hydrogen atom or a C1-C4 alkyl group; and mb means an integer of 1 or 2); R1 means hydrogen atom or a C1-C6 alkyl group; Z means a single bond or -CO-NH-; and R means a C6-C10 aryl ring or 6- to 10-membered heteroaryl ring which may have a substituent and in which a part of the ring may be saturated, respectively.